CA2142811C - Novel glucan preparation - Google Patents

Novel glucan preparation Download PDF

Info

Publication number
CA2142811C
CA2142811C CA002142811A CA2142811A CA2142811C CA 2142811 C CA2142811 C CA 2142811C CA 002142811 A CA002142811 A CA 002142811A CA 2142811 A CA2142811 A CA 2142811A CA 2142811 C CA2142811 C CA 2142811C
Authority
CA
Canada
Prior art keywords
glucan
beta
soluble
underivatized
aqueous soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002142811A
Other languages
French (fr)
Other versions
CA2142811A1 (en
Inventor
Spiros Jamas
D. Davidson Easson, Jr.
Gary R. Ostroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collaborative Group Ltd
Original Assignee
Collaborative Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/934,015 external-priority patent/US5622939A/en
Application filed by Collaborative Group Ltd filed Critical Collaborative Group Ltd
Publication of CA2142811A1 publication Critical patent/CA2142811A1/en
Application granted granted Critical
Publication of CA2142811C publication Critical patent/CA2142811C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Abstract

The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (I) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucan of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo.
Safe and efficacious preparations of neutral, aqueous soluble .beta.-glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1.beta., TNF.alpha.) that can cause detrimental side effects, such as fever and inflammation.

Description

2 ~ 42a > >
NOVF;L GLUCAN PREPARATION
Backc~-ound of the Inv~e ' n 'In the early 196~0's, zyi~osan, a crude insoluble yeast extract prepared by boiling yeast before and after trypsin treatment, was noted to produce marked hyperplasia and functional stimulation of the reticuloendothelial system in rodents. In animal studies, zymosan preparations were shown to inactivate complement component C3, to enhance antibody formation, t:o promote survival following irradiation, to increase resistance to bacterial infections, to inhibit tumor development, to promote graft rejection, and to inhibit dietary-induced hypercholesterolemia and cholesterosis. Zymosan was shown to consist of polysaccharides, proteins, fats, and inorganic elements; however, subsequent studies identified the active components. of the yeast cell wall as a pure polysaccharide, specifically ~-glucan. In conventional nomenclature, the po7.ysaccharide ~-glucan is known as poly-(1-6)-~-D-glucopyranosyl-(1-3)-~-D-glucopyranose (PGG). Repetition oi: biological assays with ~-glucan indicated that most of the above functional activities identified With zymo=:an were retained by the purified ~-glucan preparation.
The properties of ~-glucan are quite similar to those of endotoxin in. incrE:asing nonspecific immunity and resis-tance to infection. The activities of ~-glucan as an immune adjuvant. and hemopoietic stimulator compare to those of more complex biological response modifiers (BRMs), such as. baci7Llus Calmette-Guerin (BCG) and Corynebacteriua~ parvum. The functional activities of yeast /~-glucan are a7Lso comparable to those structurally similar carbohydrate polymers isolated from fungi and plants. These higher- molecular weight (1-3)-(3-D-glucans such as schizoF;hyllan, lentinan, krestin, grifolan, and s 3 ~ ~ ~ ~ PCT/US93/0791?~"

pachyman exhibit similar immunomodulatory activities. A
common mechanism shared by all these ~-glucan preparations is their stimulation of cytokines such as interleukin-1 (IL-1) and tuumor nE:crosis factor (TNF) . Lentinan has been extensively investigated for its antitumor properties, both in animal modE:ls at 1 mg/kg for 10 days and in clinical trials since the late 1970s in Japan for advanced or recurrent malignant lymphoma and colorectal, mammary, lung and gastric cancers. In cancer chemotherapy, lentinan has been administered at 0.5-5 mg/day, intramuscularly (I.M.) or intravenously (I.V.), two or three times F~er week alone, or in combination with antineoplasti.c drugs. In addition to the activities ascribed to ~~east glucans, studies suggest lentinan acts as a T-cell immunopotentiator, inducing cytotoxic activities, including production of interleukins 1 and 3 and colony-st:imulaiting factors (CSF). (Chihara gt 1989, IntJ ~J ~~hnmu~igtherativ, 4_:145-154 ; Hamuro and Chihara, In j~entinan, An Immuno~otentiator) Various preparations of both particulate and soluble ~-glucans have been tested in animal models to evaluate biological acaivities. The use of soluble and insoluble S-glucans alone or as vaccine adjuvants for viral and bacterial ani:igens has been shown in animal models to markedly increase :resistance to a variety of bacterial, fungal, protozoan .and viral infections. The hemopoietic effects of ~~-glucan have been correlated with increased peripheral blood leukocyte counts and bone marrow and splenic cellularity, reflecting increased numbers of granulocyte-~aacrophage progenitor cells, splenic pluripotent stem cells, and erythroid progenitor cells, as well as, increased serum levels of granulocyte-monocyte colony-stimulating factor (GM-CSF). Furthermore, the zl4zs~~
--~WO 94/04163 PCT/US93/07904 hemopoietic an~3 anti-infective effects of ~-glucan were active in cyclnphosphamide-treated immunosuppressed animals. S-glvucan was shown to be beneficial in animal models of trauma, wound healing and tumorigenesis.
However, various insoluble and soluble preparations of ~-glucan differe~3 significantly in biological specificity and potency, with effective dosages varying from 25 to 500 mg/kg intravenously or intraperitoneally (I. P.) in models for protection against infection and for hemopoiesis.
Insoluble preparations demonstrated undesirable toxicological properties manifested by hepatosplenomegaly and granuloma formation. Clinical interest was focused on a soluble glucan preparation which would retain biological activity yet yield negligible toxicity when administered systemically. Chronic systemic administration of a soluble phosphorylated glucan over a wide range of doses (40-1000 mg/kg) yielded negligible toxicity in animals , X4_:773-779;
(DiLuzio g~ ~., 1979, Int. J. of Cancer DiLuzio, U.S. Patent 4,739,046).
The molecular mechanism of action of ~-glucan has been elucidated by the demonstration of specific ~-glucan receptor binding sites on the cell membranes of human neutrophils and macrophages. Mannans, galactans, a(1-4)-linked glucose polymers and ~(1-4)-linked glucose polymers have no avidity for this receptor. These ~-glucan binding sites are opsanin-independent phagocytic receptors for particulate activators of the alternate complement pathway, similar to Escherichia coli lipopolysaccharide (LPS) and some animal red blood cells. Ligand binding to the ~-glucan receptor, in the absence of antibody, results in complement activation, phagocytosis, lysosomal enzyme release, and F~rostaglandin, thromboxane and leukotriene generation; thereby increasing nonspecific resistance to WO 94/04163 ~ ~ ~ ~ ~ ~ PCT/US93/0790~
infection. However, soluble ~-glucan preparations described in the prior art demonstrated stimulation of cytokines. Increases in plasma and splenic levels of interleukins 1 and 2 (IL-1, IL-2) in addition to TNF were observed 'fin 'vo and corresponded to induction of the synthesis of these cytokines 'fir vitro. (See Sherwood gt 1987, Int. J. ImmunoDharmac., x:261-267 (enhancement of IL-1 and IL-2 levels in rats injected with soluble glucan); Williams et ~., 1988, Int. J. Immunopharmac., x:405-414 (systemic administration of soluble glucan to AIDS patients increased IL-1 and IL-2 levels which were accompanied by chills and fever); Browder et ~1., 1990, Ann. Sura., x:605-613 (glucan administration to trauma patients increased serum IL-1 levels, but not TNF levels);
Adachi ~t ~1_. , 1990, Chem. Pharm. Bull . , ~: 988-992 (chemically cross-linked ~(1-3) glucans induced IL-1 production in mice).) Interleukin-1 is a primary immunologic mediator involved in cellular defense mechanisms. Numerous studies have been carried out on the application of IL-1 to enhance non-specific resistance to infection in a variety of clinical states. Pomposelli ~t ~., J. Parent. Ent.
Nutr. 12j2):212-218, (1988). The major problem associated with the excessive stimulation or exogenous administration of IL-1 and other cellular mediators in humans is toxicity and side effects resulting from the disruption of the gentle balance of the immunoregulatory network. Fauci et Ann. Int. Med., X06:421-433 (1987). IL-1 is an inflammatory cytokine that has been shown to adversely affect a variety of tissues and organs. For instance, recombinant IL-1 has been shown to cause death, hypotensive shock, leukopenia, thrombocytopenia, anemia and lactic acidosis. In addition, IL-1 induces sodium excretion, anorexia, slow wave sleep, bone resorption, decreased pain threshold and expression of many inflammatory-associated cytokines. It is also toxic to the insulin secre=ting :beta cells of the pancreas.
Patients suffering from a number of inflammatory diseases have elevated le~~els of IL-1 in their systems.
Administration o:E agents that enhance further IL-1 production only exacerbate these inflammatory conditions.
Tumor necroais factor is also involved in infection, inflammation and cancer. Small amounts of TNF release growth factors w',hile in larger amounts, TNF can cause septic shock, aches, pains, fever, clotting of blood, degradation of bone and stimulation of white blood cells and other immune defenses.
Summary of the Invention The present invention relates to neutral soluble ~-glucans which enhance a host's immune defense mechanisms to infection but do not induce an inflammatory response, -to preparations containing the neutral soluble ~-glucans, and to a novel m.anufac;turing process therefor and to their use in manufacturing medications and in their use in pharmaceutical c:ompos:itions. In the present method, solub7.e glucan Which induces cytokine production is pr'ocesse'd through a unique series of acid, alkaline and neutral treatment steps to yield a conforma-tionally pure neutral soluble glucan preparation with unique biological properties. The neutral soluble glucan preparation retains a specific subset of immunological properties common to /3-glucans but uniquely does not induce the production of IL-1 and TNF in vitro or 'fin vivo.
Throughout this speci:Eication, unless otherwise indicated, the expressions "neut:ral soluble glucan" and "neutral soluble ~-glucan" refer to the composition prepared as described in Example 1.

WO 94/04163 PCT/US93/07904 ._ 21428'1 i The neutral soluble glucan preparation is produced by treating insohible g:lucan with acid to produce a water soluble glucan,, dissociating the native conformations of the soluble glucan at alkaline pH, purifying the desired molecular weight fraction at alkaline pH, re-annealing the dissociated glucan fraction under controlled conditions of time, temperature and pH to form a unique triple helical conformation, rind further purifying under neutral pH to remove single helix .and aggregated materials to yield a conformational:ly pure, neutral, water soluble, underivatized c;lucan which has a unique biological profile .
The neutral soluble glucan preparation has a high affinity for the ~-glucan receptor of human monocytes and retains two primary biological activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes mononuclear cells to increase IL-1 and TNF production ,~ y~t~o and 'fin vivo.
The neutral soluble glucan preparation is appropriate for parenteral (e. g., intravenous, intraperitoneal, subcutaneous, intramuscular), topical, oral or intranasal administration to humans and animals as an anti-infective to combat infection associated with burns, surgery, chemotherapy, bone marrow disorders and other conditions in which the ivmmune system may be compromised. Neutral soluble glucan produced by the present method can be maintained in a clear solution and equilibrated in a pharmaceutically acceptable carrier. Safe and efficacious preparations of the neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic _,_ treatment regimens of humans and animals to enhance their immune response,, without stimulating the production of .
certain biochemical mediators (e.g., IL-1 and TNF) that .
can cause detrimental side effects, such as fever and inflammation.
Brief Description of 'the Figures Fig. 1 shoi~s the general structure of neutral soluble glucan as being a linear /3(1-3)-linked glucose polymer having periodic branclxing via a single ~(1-6)-linked to glucose moiety.
Fig. 2 shows a gel permeation chromatogram (pH 7) of soluble glucan i'hich laas not been purified by alkali dissociation an~i re-annealing. The chromatogram shows three species, referred to herein as high molecular weight aggregate (Ag), Peak i~ and Peak B (single helix glucan).
Fig. 3 is a chromatogram obtained for the neutral soluble glucan by gel permeation chromatography. The solid line.reprEaents the neutral soluble glucan at pH 7 and the broken line represents the neutral soluble glucan at pH 13.
Fig. 4 is a chromatogram obtained for the single helix ~-glucan y;Peak 33) by gel permeation chromatography.
The solid line represents Peak B at pH 7 and the broken line represents Peak 13 at pH 13.
Fig. 5 sho~rs the change in serum TNF levels, over time, taken frolll patients intravenously infused with placebo (broken line) or neutral soluble glucan (solid line) .
Fig. 6 shoc~~s the change in serum IL-1 levels, over time, taken from patients intravenously infused zaith placebo (broken line) or neutral soluble glucan (solid line) .
iB

WO 94/04163 PCT/US93/07904 .,~

_8-Fig. 7 is a diagram representing peripheral blood counts from irradiated mice following administration of neutral soluble glucan.
Fig. 8 is a diagram representing platelet cell counts from cisplatin-treated mice following administration of neutral soluble gluca:n.
Detailed Descrig~g~ of Invention The invention relates to a neutral soluble ~-glucan polymer that ca.n bind to the ~-glucan receptor and activate only a. desired subset of immune responses. The terms "neutral solub7.e ~-glucan" and "neutral soluble glucan", unless, otherwise specified, refer to the composition prepared as described in Example 1.
This neutral soluble ~-glucan has been shown to Increase the number of neutrophils and monocytes as well as their direct: infecaion fighting activity (phagocytosis and microbial x:illinc~). However, the neutral soluble glucan does not: stimulate the production of biochemical mediators, such as Ih-1 and TNF, that can cause detrimen-tal side effecta such as high fever, inflammation, wasting disease and organ failure. These advantageous properties make neutral soluble glucan preparations of this invention useful in the preveni~ion and treatment of infection because they sE:lectively activate only those components of the immune system re:aponsible for the initial response to infection, without sltimulating the release of certain biochemical mediator:a that can cause adverse side effects.
The solution containing the neutral soluble ~-glucan also lacks the toxicity common to many immunomodulators.
The neutral soluble ~B-glucans of this invention are composed of glucose monomers organized as a ~B(1-3) linked glucopyranose backbone with periodic branching via ~(1-6) 'WO 94/04163 214 2 ~ 1 i PCT/US93/07904 -g-glycosidic linkages. The neutral soluble glucan prepara-tions contain glucans;, which have not been substantially modified by sub~stitut:ion with functional (e. g., charged) groups or other covalent attachments. The general structure of the neutral soluble glucan is shown in Fig.
1. The biologically active preparation of this invention is a conformationally purified form of ~-glucan produced by dissociating' the native glucan conformations and re-annealing and purifying the resulting unique triple helical conformation. The unique conformation of the neutral soluble: glucan contributes to the glucan's ability to selectively activate the immune system without stimulating the: production of detrimental biochemical mediators.
The neutral soluble glucan preparations of this invention are prepared from insoluble glucan particles, preferably derived from yeast organisms. See Manners ~t ~, Biochem. J_, ~i:19-30, (1973) for a general procedure to make insoluble yeast glucans. Glucan particles which are particularly useful as starting materials in the present invention are whole glucan particles (WGP) described by Jamas et ., in U.S. Patent Nos. 4,810,646, 4,99:?,540, 5,082,936 and 5,028,703, the teachings of al.l of which are hereby incorporated herein by reference. The source of the whole glucan particles can be the broad spectrum of glucan-containing yeast organisms whicri contain ~-glucans in their cell walls.
Whole glucan particles obtained from the strains Saccharomvces r._erevi:>iae R4 (NRRL Y-15903; deposit made in connection with U.S. Patent No. 4,810,646) and R4 Ad (ATCC
No. 74181) are particularly useful. Other strains of yeast that can be used include Saccharomyces delbrueckii, Saccharomyces rosei, Saccharomyces microelligsodes, Saccharomyces c:ar s E~rgensis,-. Schizosaccharom c~ pombe, Kluyveromyces J.ac 's" Kl.uyveromyces fraQilis, Kluyveromyces ~~olyspc~rus, Candida albicans, Candida cloacae, Candicla trop'ca 's Candida utilis ~iansenula , , win ei ansenu a -,~'v, ~iansenula henricii, hansenula americana.

A procedure for extraction of whole glucan particles is described by' Jama:~ et al. , in U. S. Patent Nos.

4,810,646, 4,99'2,540,. 5,082,936 and 5,028,703. For the l0 purpose of this; present invention, it is not necessary to conduct the final organic extraction and wash steps de-scribed by Jama.s et In the preaent process, whole glucan particles are suspended in an acid solution under conditions sufficient to dissolve the: acid--soluble glucan portion. For most glucans, an acid solution having a pH of from about 1 to about 5 and at a temperature of from about 20 to about 100C is sufficient. Preferably, the acid used is an organic acid capable of dissolving the acid-soluble glue portion. Acetic acid, at concentrations of from about 0.1 to about 5 M or formic acid at concentrations of from about 50% to 98% (w/m) are useful for this purpose. The treatment time may vary from about l0 minutes to about 20 hours depending) on the acid concentration, temperature and source of whole: glucan particles. For example, modified glucans having more X3(1-6) branching than naturally-occurring, or ~~ild-type glucans, require more stringent conditions, i.e., longer exposure times and higher ' temperatures. This acid-treatment step can be repeated under similar car variable conditions. One preferred processing method is described in the exemplification using glucan derived from S. cerevisiae strain R4 Ad. In another embodiment oi= the present method, whole glucan iE

~~!O 94/04163 ~ ~ ~ PCT/US93/07904 particles from t:he strain, S. cerevisiae R4, which have a higher level of ~(1-6) branching than naturally-occurring glucans, are usE:d, and treatment is carried out with 90%
(w/v) formic ac~.d at a0°C for about 20 minutes and then at 85 ° C f or about ?~ 0 minutes .
The insoluble glucan particles are then separated from the solution by an appropriate separation technique, for example, by centrifugation or filtration. The pH of the resulting s7.urry :is adjusted with an alkaline compound such as sodium hydroxide, to a pH of about 7 to about 14.
The precipitate is co:Llected by centrifugation and is boiled in purified wai;.er (e.g., USP) for three hours. The slurry is then resuspeanded in hot alkali having a concentration sufficient to solubilize the glucan polymers. Alkaline compounds which can be used in this step include alts:ali-mental or alkali-earth metal hydroxides, such as sodium hydroxide or potassium hydroxide, having a concentration of from about 0.01 to about 10 N. This step can be conducted at a temperature of from about 4°'C to about 121°C, preferably from about 20°C to about 100°C. In one embodiment of the process, the conditions utilized are a 1 M solution of sodium hydroxide at a temperature of about 80-100°C and a contact time of approximately 1-2 hours. The resulting mixture contains solubil.ized c~lucan molecules and particulate glucan residue amd generally has a dark brown color due to oxidation of cor.~taminating proteins and sugars. The particulate residue is removed from the mixture by an appropriate separation technique, e.g., centrifugation and/or filtration. In another embodiment of the process the acid-soluble: glucans are precipitated after the preceding acid hydrolysis reaction by the addition of about 1.5 volumea of Eahanol. The mixture is chilled to WO 94/04163 PCT/US93/07904_ z~~zsm about 4°C for two (2) hours and the resulting precipitate is collected by centrifugation or filtration and washed with water. The pellet is then resuspended in water, and stirred for three (3) to twelve (12) hours at a temperature between about 20°C and 100°C. At this point the pH is adjusted to approximately 10 to 13 with a base such as sodium hydroxide.
The resulting solution contains dissociated soluble glucan molecules. This solution is now purified to remove traces of insoluble glucan and high molecular weight soluble glucans which can cause aggregation. This step can be carried out by an appropriate purification technique, for example, by ultrafiltration, utilizing membranes with nominal molecular weight (NMW) levels or cut-offs in the range of about 1,000 to 100,000 daltons.
It was discovered that in order to prevent gradual aggregation or precipitation of the glucan polymers the preferred membrane for this step has a nominal molecular weight cut-off of about 100,000 daltons. The soluble glucan is then further purified at alkaline pH to remove low molecular weight materials. This step can be carried out by an appropriate purification technique, for example, by ultrafiltration, utilizing membranes with nominal molecular weight levels or cut-offs in the range of 1,000 to 30,000 daltons.
The resulting dissociated soluble glucan is re-annealed under controlled conditions of time (e. g., from about 10 to about 120 minutes), temperature (e. g., from about 50 to about 70°C) and pH. The pH of the solution is adjusted to the range of about 3.5-11 (preferably 6-8) with an acid, such as hydrochloric acid. The purpose of this re-annealing step is to cause the soluble glucan to rearrange from a single helix conformation to a new 2~4~811 VI~n 94/04163 PCT/US93/07904 ordered triple helical conformation. The re-annealed glucan solution .is then size fractionated, for example by using 30,000-70,~D00 NMW and 100,000-500,000 NMW cut-off membrane ultrafi.lters to selectively remove high and low molecular weight soluble glucans. Prior to sizing, the soluble glucans .exist as a mixture of conformations including random coils, gel matrices or aggregates, triple helices and single helices. The objective of the sizing step is to obtain an enriched fraction for the re-annealed conformation of ;specific molecular weight. The order in which the ultraf.ilters are used is a matter of preference.
The concent:rated fraction obtained is enriched in the soluble, biologi~~ally active neutral soluble glucan. The glucan concentrate is further purified, for example, by diafiltration using a 10,000 dalton membrane. The preferred concentration of the soluble glucan after this step is from about 2 to about 10 mg/ml.
The neutralized solution can then be further purified, for ex~~mple, by diafiltration, using a pharmaceutically acceptable medium (e. g., sterile water for injection, plnosphate-buffered saline (PBS), isotonic saline, dextrose) suitable for parenteral administration.
The preferred me»brane for this diafiltration step has a nominal molecular weight cut-off of about 10,000 daltons.
The final concentration of. the glucan solution is adjusted in the range of .about 0.5 to 10 mg/ml. In accordance with pharmaceutical manufacturing standards for parenteral products, the solution can be terminally sterilized by filtration through a 0.22 ~,m filter. The neutral soluble glucan preparation obtained by this process is sterile, non-antigenic, essentially pyrogen-free, and can be stored at room temperature (e. g., 15-30°C) for extended periods of time without degradation. This process is unique in WO 94/04163 PCT/US93/07904 _.
~14~811 that it results in a neutral aqueous solution of (pH 4.5 to 7.0) immunologically active glucans which is suitable for parenteral administration.
For purposes of the present invention, the term "soluble" as used herein to describe glucans obtained by the present process, means a visually clear solution can be formed in an aqueous medium such as water, PBS, isotonic saline, or a dextrose solution having a neutral pH (e. g., from about pH 5 to about 7.5), at room temperature (about 20-25°C) and at a concentration of up to about 10 mg/ml. The term "aqueous medium" refers to water and water-rich phases, particularly to pharmaceutically acceptable aqueous liquids, including PBS, saline and dextrose solutions. The expression i5 "visually clear" means that at a concentration of 1 mg/ml, the absorption of the solution at 530 nm is less than OD
0.01 greater than the OD of an otherwise identical solution lacking the B-glucan component.
The resulting solution is substantially free of protein contamination, is non-antigenic, non-pyrogenic and is pharmaceutically acceptable for parenteral administration to animals and humans. However, if desired, the soluble glucan can be dried by an appropriate drying method, such as lyophilization, and stored in dry form.
The neutral soluble glucans of this invention can be used as safe, effective, therapeutic and/or prophylactic agents, either alone or as adjuvants, to enhance the immune response in humans and animals. Soluble glucans produced by the present method selectively activate only those components that are responsible for the initial response to infection, without stimulating or priming the immune system to release certain biochemical mediators ~19~~8~~
~~VO 94/04163 PCT/US93/07904 (e. g., IL-1, TNF, IL-6, IL-8 and GM-CSF) that can cause adverse side eiFfects. As such, the present soluble glucan composition can be used to prevent or treat infectious diseases in ma:lnouri;shed patients, patients undergoing surgery and bone marrow transplants, patients undergoing chemotherapy or radiotherapy, neutropenic patients, HIV-infected patients, trauma patients, burn patients, patients with chronic or resistant infections such as those resulting from myelodysplastic syndrome, and the elderly, all o:E who :may have weakened immune systems. An immunocompromi,~ed individual is generally defined as a person who exhibits an attenuated or reduced ability to mount a normal cellular and/or humoral defense to challenge by infectious agents, e.g., viruses, bacteria, fungi and protozoa. A protein malnourished individual is generally defined as a person who has a serum albumin level of less 'than about 3.2 grams per deciliter (g/dl) and/or unintentional weight loss of greater than 10% of usual body weight.
More particularly, the method of the invention can be used to therapeutically or prophylactically treat animals or humans who .are at a heightened risk of infection due to imminent surgery, injury, illness, radiation or chemotherapy, or other condition which deleteriously affects the immune system. The method is useful to treat patients who have a disease or disorder which causes the normal metabolic imtfl~une response to be reduced or depressed, such as HIV infection (AIDS). For example, the method can be used t.o pre-initiate the metabolic immune response in patients. who are undergoing chemotherapy or radiation therapy, or who are at a heightened risk for developing secondary infections or post-operative complications because of a disease, disorder or treatment WO 94/04163 2 ~ 4 2 81 1 PCT/US93/07904 resulting in a reduced ability to mobilize the body's normal metabolic responses to infection. Treatment with the neutral soluble glucans has been shown to be particularly effective in mobilizing the host's normal immune defenses, thereby engendering a measure of protection from infection in the treated host.
The present composition is generally administered to an animal or a human in an amount sufficient to produce immune system enhancement. The mode of administration of the neutral soluble glucan can be oral, enteral, parenter-al, intravenous, subcutaneous, intraperitoneal, intramuscular, topical or intranasal. The form in which the composition will be administered (e. g., powder, tablet, capsule, solution, emulsion) will depend upon the route by which it is administered. The quantity of the composition to be administered will be determined on an individual basis, and will be based at least in part on consideration of the severity of infection or injury in the patient, the patient's condition or overall health, the patient's weight and the time available before surgery, chemotherapy or other high-risk treatment. In general, a single dose will preferably contain approximately 0.01 to approximately 10 mg of modified glucan per kilogram of body weight, and preferably from about 0.1 to 2.5 mg/kg. The dosage for topical application will depend upon the particular wound to be treated, the degree of infection and severity of the wound. A typical dosage for wounds will be from about 0.001 mg/ml to about 2 mg/ml, and preferably from about 0.01 to about 0.5 mg/ml.
In general, the compositions of the present invention can be administered to an individual periodically as necessary to stimulate the individual's immune response.

~~O 94/04163 ~ ~ ~ ~ PCT/US93/07904 An individual sls;filled in the medical arts will be able to determine the lE:ngth of time during which the composition is administered and the dosage, depending upon the physical condition of the patient and the disease or disorder being treated. As stated above, the composition may also be used as a preventative treatment to pre-initiate the normal metabolic defenses which the body mobilizes against infections.
Neutral soluble /~-glucan can be used for the prevention and treatment of infections caused by a broad spectrum of bact:erial,, fungal, viral and protozoan pathogens. The proph~~lactic administration of neutral soluble ~-glucar: to a person undergoing surgery, either preoperatively, intraoperatively and/or post-operatively, will reduce the incidence and severity of post-operative infections in both normal and high-risk patients. For example, in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated (e. g., gastrointestinal surgery, hysterectomy, cesarean section, transurethra:l prostatectomy) and in patients in whom infection e:t the operative site would present a serious risk (e.,g., p;rosthetic arthroplasty, cardiovascular :aurger;Y), concurrent initial therapy with an appropriate eintibacterial agent and the present neutral soluble glucan ~~reparation will reduce the incidence and severity of infE:ctiou;s complications.
In patient:a who are immunosuppressed, not only by disease (e. g., cancer, AIDS) but by courses of chemother-apy and/or radiotherapy, the prophylactic administration of the soluble c~lucan will reduce the incidence of infections causEad by .a broad spectrum of opportunistic pathogens including many unusual bacteria, fungi and viruses. Therapy using neutral soluble ~-glucan has WO 94/04163 ~ ~ ~ ~ ~ ~ ~ PCT/US93/0790~

demonstrated a significant radio-protective effect with its ability to enhance and prolong macrophage function and regeneration and, as a result enhance resistance to microbial invasion and infection.
In high risk patients (e. g., over age 65, diabetics, patients having cancer, malnutrition, renal disease, emphysema, dehydration, restricted mobility, etc.) hospitalization frequently is associated with a high incidence of serious nosocomial infection. Treatment with neutral soluble ~-glucan may be started empirically before catheterization, use of respirators, drainage tubes, intensive care units, prolonged hospitalizations, etc. to help prevent the infections that are commonly associated with these procedures. Concurrent therapy with antimi-crobial agents and the neutral soluble ~B-glucan is indicated for the treatment of chronic, severe, refractory, complex and difficult to treat infections.
The compositions administered in the method of the present invention can optionally include other components, in addition to the neutral soluble ~-glucan. The other components that can be included in a particular composition are determined primarily by the manner in which the composition is to be administered. For example, a composition to be administered orally in tablet form can include, in addition to neutral soluble ~-glucan, a filler (e. g., lactose), a binder (e. g., carboxymethyl cellulose, gum arabic, gelatin), an adjuvant, a flavoring agent, a coloring agent and a coating material (e.g., wax or plasticizer). A composition to be administered in liquid form can include neutral soluble ~-glucan and, optionally, an emulsifying agent, a flavoring agent and/or a coloring agent. A composition for parenteral administration can be mixed, dissolved or emulsified in water, sterile saline, 214~~~.1 ~u0 94/04163 PBS, dextrose or other biologically acceptable carrier. A
composition for topical administration can be formulated into a gel, ointment, lotion, cream or other form in which the composition is capable of coating the site to be treated, e.g., 'wound site.
Compositions comprising neutral soluble glucan can also be administered topically to a wound site to stimulate and enhance wound healing and repair. Wounds due to ulcers, .acne, viral infections, fungal infections or periodontal disease, among others, can be treated according to the methods of this invention to accelerate the healing pro~~ess. Alternatively, the neutral soluble ~-glucan can be injected into the wound or afflicted area.
In addition to wound repair, the composition can be used to treat infection associated therewith or the causative agents that result in the wound. A composition for topical administration can be formulated into a gel, ointment, lotion, cream or other form in which the composition is capable of coating the site to be treated, e.g., wound site. The dosage for topical application will depend upon the particular wound to be treated, the degree of infection and severity of the wound. A typical dosage for wounds will be from about 0.01 mg/ml to about 2 mg/ml, and preferably :from about 0.01 to about 0.5 mg/ml.
Another particular use of the compositions of this invention is four the treatment of myelodysplastic syndrome (l~S). MDS, frequently referred to as preleukemia syndrome, is a ~~roup of clonal hematopoietic stem cell disorders characterized by abnormal bone marrow differentiation and maturation leading to peripheral cytopenia with high probability of eventual leukemic conversion. Recurrent infection, hemorrhaging and terminal infection resulting in death typically accompany PCT/US93/079(1Q

MDS. Thus, in order to reduce the severity of the disease and the frequency of infection, compositions comprising modified glucan can be chronically administered to a patient diagnosed as having MDS according to the methods of this invention, in order to specifically increase the infection fighting activity of the patient's white blood cells. Other bone marrow disorders, such as aplastic anemia (a condition of quantitatively reduced and defective hematopoiesis) can be treated to reduce infection and hemorrhage that are associated with this disease state.
Neutral soluble glucan produced by the present method enhances the non-specific defenses of mammalian mononuclear cells and significantly increases their ability to respond to an infectious challenge. The unique property of neutral soluble glucan macrophage activation is that it does not result in increased body temperatures (i.e., fever) as has been reported with many non-specific stimulants of those defenses. This critical advantage of neutral soluble glucan may lie in the natural profile of responses it mediates in white blood cells. It has been shown that the neutral soluble ~B-glucan of the present invention selectively activates immune responses but does not directly stimulate or prime cytokine (e.g., IL-1 and TNF) release from mononuclear cells, thus distinguishing the present neutral soluble glucan from other glucan preparations (e.g., lentinan, kresein) and immunostimulants.
In addition, it has been demonstrated herein that the neutral soluble glucan preparation of the present invention possesses an unexpected platelet stimulating property. Although it was known that glucans have the ability to stimulate white blood cell hematopoiesis, the 2~3.4~811 disclosed platcalet stimulating property had not been reported or ani~icipa~ted. This property can be exploited in a therapeutic regimen for use as an adjuvant in parallel with radiation or chemotherapy treatment.
Radiation and chemotherapy are known to result in neutropenia (rcaduced polymorphonuclear (PMN) leukocyte cell count) and thro;mbocytopenia (reduced platelet count).
At present, these conditions are treated Dy the administration of colony-stimulating factors such as GM-IO CSF and granulocyte colony-stimulating factor (G-CSF).
Such factors ace effective in overcoming neutropenia, but fail to impact upon thrombocytopenia. Thus, the platelet stimulating property of the neutral soluble glucan preparation of this invention can be used, for example, as a therapeutic ~~gent to prevent or minimize the development of thrombocyto~~enia which limits the dose of the radiation or chemotherap~eutic agent which is used to treat cancer.
The invention is further illustrated by the following Examples.

~~ 4zs~~

EXAMPLES
EXAMPLE l: PREPARATION OF NEUTRAL SOLUBLE GLUCAN
FROM S. CEREVISIAE
Saccharomvces cerevisiae strain R4 Ad (a non-recombi-pant derivative of wild-type strain A364A), was grown in a large-scale fermentation culture using a defined glucose, ammonium sulfate minimal medium. The production culture was maintained under glucose limitation in a feed-batch mode (New Brunswick MPP80). When the growing culture reached late logarithmic phase, the fermentation was ended and the ~-glucan was stabilized by adjusting the culture to pH 12 ~ 0.5 using 10 M NaOH. The yeast cells containing ~-glucan were harvested by continuous-flow centrifugation (Westfalia SA-1). After centrifugation, the cells were collected into a stainless steel extraction vessel.
The first step in the extraction process was an alkaline extraction accomplished by mixing the cells with 1 M sodium hydroxide (NaOH) at 90 ~ 5°C for 1 hour. Upon completion of this alkaline extraction, the ~B-glucan remained in the sclid phase, which was collected by continuous centrifugation (Westfalia SA-1). The collected cell wall fraction was extracted a second time using the same procedure and under the same conditions. Treatment with alkali hydrolyzed and solubilized the cellular proteins, nucleic acids, mannans, soluble glucans and polar lipids into the supernatant fraction, and deacety-lated chitin to chitosan in the cell wall.
The second step in the extraction process was a pH
4.5 ~ 0.05 (adjusted with concentrated HC1) extraction at 75 ~ 5°C for 1 hour. This was followed by a 0.1 M acetic acid extraction to complete the removal of glycogen, 21~281~
!~'~ 94/04163 PCT/US93/07904 chitin, chitosan and remaining proteins. The solids were collected and rinsed itwice with Purified Water USP to remove any residual acid as well as any yeast degradation products.
The third step in the extraction process was a set of six organic ext:-actions. The first four extractions were carried out in isopropanol. The solids were collected by centrifugation and then subjected to two acetone extrac-tions. The two--stage organic extractions eliminated nonpolar lipids and h!~drophobic proteins which may have co-purified with the drug substance. The resulting wet solids were dried in a vacuum oven at 65 ~ 5°C for 48-96 hours to yield ei free~-flowing powder.
At this stage the extraction process yielded a stable, insolub7le intermediate consisting of approximately 90% ~-glucan, celled tahole glucan particles (WGPs). The dry WGP intermediate was stored at 15-30°C until further use.
The WGP powder was resuspended in 98% (w/v) formic acid, in a glass reacition vessel at room temperature. The resulting mixture was heated to 85 ~ 5°C for 20 minutes.
Under these condition;a, the WGPs were partially hydrolyzed and solubilized to provide the desired molecular weight distribution of soluble ~-glucan which was then precipitated by adding 1.5 volumes of ethanol. After complete mixing,, the preparation was centrifuged to collect the ~-glucan precipitate. Any residual formic acid was removed by boiling the ~-glucan preparation in Purified Water Z1SP for three hours.
Any unhydrolyzed WGPs were then removed from the glucan solution by centrifugation. The ~-glucan solution was raised to pFi 12.5 ~ 0.5 by the addition of the concen-WO 94/04163 PCT/US93/0790~-~~4~811 trated sodium hydroxide. The remaining purification steps were carried out by ultrafiltration.
The soluble alkaline ~-glucan preparation was passed through a 100,000 nominal molecular weight (NMW) cut-off membrane ultrafilter (Amicon DC10). Under alkaline conditions this membrane ultrafilter removed insoluble and high molecular weight soluble ~-glucan. Trace low molecular weight degradation products were then removed by recirculation through a 10,000 NMW cut-off membrane ultrafilter. The ultrafiltration was conducted as a constant volume wash with 0.1 M NaOH.
The ~-glucan solution was re-annealed under controlled conditions by adjusting the pH to 7.0 ~ 0.5 with concentrated hydrochloric acid, heating to 60 ~ 10°C, which was maintained for 20 minutes and then cooled. The neutral re-annealed solution was then concentrated and washed with Sodium Chloride Injection USP in a 70,000 NMW
cut-off membrane ultrafilter (Filtron Minisep) to enrich for the re-annealed neutral soluble glucan. Next the material was filtered through a 300,000 NMW cut-off membrane ultrafilter (Filtron Minisep) to remove high molecular weight and aggregated glucan molecules. In the same ultrafilter, the neutral soluble glucan material was washed with Sodium Chloride Injection USP in a constant volume wash mode.
The neutral soluble glucan was then concentrated in a 10,000 NMW cut-off membrane ultrafilter. The concentration process continued until a concentration of at least 1.0 mg/ml hexose equivalent was achieved.
The resulting neutral soluble glucan was then subjected to filtration through a depyrogenating filter (0.1 micron Posidyne) and a sterile 0.2 micron filter (Millipak) to yield sterile, pyrogen-free neutral soluble "'10 94/04163 2 ~ 't t~ ~ ~ ~ PCT/US93/07904 glucan. The neutral ~.oluble glucan solution was stored at controlled room temperature (15-30°C) until further use.
The aqueous solubility of neutral soluble glucan in the pH
range of 4 to 8 is approximately 100 mg/ml. The solubil-ity increased with increasing pH and reached approx. 150 mg/ml at pH 13.
EXAMPLE 2: ANAhYSIS ()F NEUTRAL SOLUBLE GLUCAN
A. Glucose. Mar~nose rind Glucosamine Monosaccharide analysis was performed to quantitate l0 the relative amounts of ~B-glucan (as glucose), mannan or phosphomannan (ass mannose), and chitin (as N-acetyl glucosamine) in the neutral soluble glucan. The sample was hydrolyzed t:o monosaccharides in 2 M trifluoroacetic acid for 4 hours at 1:L0°C, evaporated to dryness, and redissolved in water. Monosaccharides were separated on a Dionex HPLC system using a CarboPac PA100 column (4 x 250 mm) using 5 M Na~OH at 1 ml/min and quantitated using a pulsed electrocriemica:l detector (Dionex Model PED-1). The sensitivity of this assay for monosaccharides is 0.1%
(w/w) .
Glucose (reaention time of 16.6 min) was identified as the only monosaccharide component of neutral soluble glucan along with traces of glucose degradation products (from hydrolysi:c) anhl~droglucose at 2.5 min and 5-hydroxymethylfurfural at 4.3 min. The results confirm that neutral so7.uble glucan consisted of z98% glucose.
B. FTIR
Fourier tra~nsfona infrared spectroscopy by diffuse reflectance (FT7:R, Matson Instruments, Polaris) of lyophi-lined neutral soluble glucan samples was used to determine the anomeric st:-uctur~e (a vs. ~), and linkage type (~(1-z~4~$~1 3), ~(1-6), ~(1-4)) present in neutral soluble glucan.
Absorption maxima of 890 cm'' identified ~(1-3) linkages;
920 cm'' identified ~(1-6) linkages. No presence of c-linked anomers (e. g., glycogen, 850 cm'') or ~(1-4)-linked polysaccharides (e. g., chitin, 930 cm') were detected.
EXAMPLE 3: CONFORMATIONAL ANALYSIS
A solution of ~-glucan which was not processed by alkali dissociation and re-annealing was analyzed for its compositional identity by gel permeation chromatography IO (pH 7) and found to contain multiple species, referred to herein as high molecular weight aggregate (Ag), Peak A and Peak B (See Figure 2). Neutral soluble glucan which was prepared by alkali dissociation and re-annealing as described in Example 1, is present as a single peak (see Figure 3) with an average molecular weight of 92,660 daltons at pH 7. The distinct conformations of neutral soluble glucan and Peak B were demonstrated by gel permeation chromatography at pH 7 and pH 13 using a refractive index detector. Neutral soluble glucan under-went a significant conformational transition from pH 7 to pH I3 which illustrates complete dissociation of the multiple helix at pH 7 to a single helical form at pH 13 (see Fig. 3). In contrast, Peak B only underwent a slight shift in molecular weight from pH 7 to pH 13 (see Fig. 4).
The molecular weight of neutral soluble glucan and Peak B
glucans as a function of pH is shown below in Table 1.

X142$11 Table 1 Sample MW MW Ratio pH 7 pH 13 (pH 7/pH 13) Neutral soluble 92,666 18,693 4.96 glucan Peak B 8,317 7,168 1.16 .The conformation of neutral soluble glucan and Peak B
glucan was also dete:nained by aniline blue complexing (Evens gt ~., 1984, Carb. Pol., 4:215-230; Adachi g~ ~., 1988, Carb. Red., ,x'7:91-100), using curdlan, a linear ~(1-3) glucan, as the triple helix control and pustulan, a ~(1-6) glucan, as a non-ordered conformational control.
The results are discussed below and shown in Table 2.
The curdlan triple helix control complexed with aniline blue resulting in high fluorescence. Increasing the NaOH concentration began to dissociate the curdlan triple helix slightly, but NaOH concentrations >0.25 M are required for complete dissociation of curdlan. The pustulan non-ordered control only formed a weak complex with aniline blue reaulting in low fluorescence measurements which were not affected by NaOH
concentration.
The neutral soluble glucan complexed effectively with aniline blue at low NaOH concentration (25mM NaOH) resulting in high fluorescence. However, the neutral soluble glucan conformation dissociated significantly (50$) at NaOH concentrations as low as 150 mM NaOH

WO 94/04163 ~ ~, PCT/US93/07904 indicating that it exists as a unique conformation compared to naturally occurring ~-glucans, such as laminarin and curdlan, which require significantly higher NaOH concentrations for dissociation to occur. Peak B
formed a weak complex with aniline blue due to its single helical conformation.
Table 2 Conformational Analysis of Glucans by Aniline Blue Complexing Fluorescence Test Material 25 mM 0~ 0 mM 51 0 mM

NaOH NaOH NaOH

Blank 0 2 0 Curdlan 53.5 41.6 36 ~(1-3) glucan Pustulan 9.8 8.3 8.0 ~S ( 1-6 ) glucan Neutral soluble glucan 40 25.6 20.2 Peak B 12.4 6.2 4.1 EXAMPLE 4: EFFECTS OF NEUTRAL SOLUBLE GLUCAN ON HUMAN
MONOCYTE PRODUCTION OF TNFa Human peripheral blood mononuclear cells were isolated (Janusz et ., (1987), J. Immunol., ~: 3897-5 3901) from normal citrated and dextran-treated blood, washed in Hank's balanced salt solution (HBSS), lacking calcium, magnesium, and phenol red, and purified by gradient centrifugation on cushions of Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ). The mononuclear cells were collected into HBSS, washed twice, ~~.4~~1I
"'~O 94/04163 PCT/US93/07904 resuspended in RPMI 1Ei40 Medium (Gibco, Grand Island, NY) containing 1% heat-inaictivated autologous serum (56°C for 30 min.), and ca~unted on the Coulter counter.
For the preparation of monocyte monolayers, 1 ml of 2.2 x 106 mononuclear cells/ml was plated into wells of 24-well tissue culturE: plates (Costar, Cambridge, MA), incubated for 1 hour at 37°C in a humidified atmosphere of 5% COZ, and washed three times with RPMI to remove nonadherent cells. A second 1 ml aliquot of 2.2 x 106 mononuclear cells/ml was layered into each well and incubated for 2 hours described above before removal of the nonadherent cells. By visual enumeration at 40X with an inverted phase microscope and a calibrated reticle, the number of adherent cells for 30 different donors was 0.77 f 0.20 X 106 per well (mean ~ SD). By morphology and nonspecific esterase staining, >95% of the adherent cells were monocytes.
Monocyte monolaye:rs were incubated at 37°C in the COZ
chamber for 0 to 8 hours with 0.5 ml of RPMI, 1% heat-inactivated autologou:c serum, 10 mM HEPES, and 5 mM MgCh in the absence and preaence of various glucan prepara-tions. The culture supernatant was removed, clarified by centrifugation at 14,000 g for 5 min at 4°C, and stored at -70°C before assay of TNFa.
The concentration of TNFa in the monocyte super-natants was measured by an enzyme-linked immunoadsorbent assay (ELISA) with the: BIOKINE TNF Test kit (T Cell Sciences, Cambridge, MA), which had a lower limit of detectability of 40 pc~/ml. The data are expressed as pg per 106 monocytea, which was calculated by dividing the quantity of cyto~kine in 0.5 ml of supernatant by the number of monocytes pe:r well.

For the determination of cell-associated levels of TNFa, the adherent monocytes were lysed in 0.25 ml PBS by three rounds of freezing and thawing, the lysates were cleared of debris by centrifugation at 14,000 g for 5 min at 4°C, and the resulting supernatants were stored at -70°C. Newly prepared monocyte monolayers contained no detectable levels of intracellular TNFa.
The results are shown in Tables 3 and 4 below.
Table 3 TNFa Synthesis by Human Monocytes Stimulated with Various Glucan Preparations TNFa (pg/106 monocytes) ~lucan Conc. 1 2 3 MeanSD

Buffer Control 36 39 2 2621 Neutral soluble img/ml 44 51 33 439 glucan Laminarin img/ml 372 324 227 30874 Whole Glucan particles 4X10~/ml 2129 1478 1683 1763333 NCO 94/04163 ~ ~ ~ ~ ~ PCT/US93/07904 Table 4 TNFa Stimulation by Different Conformational Sl:ructu:res of Soluble ~-Glucan TNFa Glucan Conc. (pg/106 monocytes) Buffer Control 1 mg/ml 40 Laminarin 1 mg/ml 1312 Neutral soluble glucan 1 mg/ml 16 Peak B 1 mg/ml 1341 Glucan Particle:a 4 X 10~/ml 2065 Table 3 shows that TNFa was stimulated by insoluble glucan particles and by laminarin, a soluble ~(1-6) and ~(1-3) linked g7~.ucan. There was no stimulation of TNFa by neutral soluble glucan. Table 4 shows similar results, but further con~:irms that TNFa stimulation is dependent upon conformational structure. The neutral soluble glucan did not stimulate TNFa while Peak B (single helical conformation) did stimulate TNFa.
EXAMPLE 5: ~~VIDIT'i~ OF NEUTRAL SOLUBLE GLUCAN FOR THE
S~LUCAN RECEPTOR
Monolayers of hwaan monocytes, prepared on siliconized gla:a coverslips (Czop et al., 1978, 7~.
Immunol., ~,~:17.32), were incubated for 18 minutes at 37°C
in a humidified 5% CO, incubator with either 0.25 ml of buffer (RPMI-Mg--HEPES) or a range of concentrations (0.1-50 ~g/ml) of neutral :soluble glucan. The monocyte monolayers were then taashed twice with 50 ml of RPMI 1640 medium and were layered with 0.25 ml of 4.8 x 106/ml zymosan particles (Czop and Austere, 1985, J. Immunol., x:2588-2593). After a 30 minute incubation at 37°C, the monolayers were washed three times with 50 ml of Hank's balanced salt solution to remove noningested zymosan particles. The monolayers were then fixed and stained with Giemsa. The ingestion of zymosan particles by at least 300 monocytes per monolayer was determined by visual observation under a 1000X light microscope.
Monocyte monolayers pretreated with buffer, 50 or 500 ~Cg/ml of neutral soluble glucan as described above were subsequently tested for their capacity to ingest IgG
coated sheep erythrocytes (E'IgG). After an 18 minute preincubation with the neutral soluble glucan, the monolayers were incubated with 0.25 ml of 1 x 10'/ml E'IgG
for 30 minutes at 37°C, washed three times with 50 ml of Hank's balanced salt solution, treated for 4 minutes with 0.84% NH,C1 to lyse noningested E'IgG, and fixed and stained as described above. The percentages of monocytes ingesting >_ 1 and >_ 3 E'IgG were determined by counting at least 300 monocytes per monolayer.
The percent inhibition of monocyte ingestion was detenained by subtracting the percentage of monocytes ingesting targets after pretreatment with the neutral soluble glucan from the percentage ingesting targets after pretreatment with buffer, dividing this number by the percentage ingesting targets after pretreatment with buffer and multiplying by 100. The data are expressed as the mean of two experiments and are reported in Table 5.

2~ 4zs~~ i Table 5 Glucan-receptor Binding Capacity of Distinct Conformations of Soluble ~-glucans Test Material Conc. % Inhibition Buffer - 0%
Neutral soluble: glucan 50 ~cg/ml 74%
500 ~tg/ml 86%
Peak B 50 ~g/ml 50%
500 ~tg/ml 56%
Both ~-glucan preparations tested above inhibited monocyte ingestion o~f zymosan particles demonstrating their capacity to competitively bind to the ~-glucan receptor on human mo~nocytes. Neutral soluble glucan demonstrated a higher receptor binding capacity than Peak B as indicated by the greater level of inhibition achieved at both 50 ~cg/ml and 500 y~g/ml. This biological assay demonstrates that the neutral soluble glucan is a superior ligand for the ~-glucan receptor.
EXAMPLE 6: ~CK,OF IN VITRO STIMULATION OF IL-18 AND Z'NFct FROM HUMAN MONONUCLEAR CELLS
Venous blood ways obtained from healthy male volun-teers and mononuclear cells were fractionated by Ficoll-Hypaque centrifugation. The mononuclear cells were washed, resuspe:nded in endotoxin-free RPMI-1640 culture medium - ult:rafiltered to remove endotoxins as described elsewhere (Dinarello et al., 1987, J. Clin.

Microbiol. x:1233-8) - at a concentration of 5 x 106 cells/ml and were aliquoted into 96-well microtiter plates (Endres stet al., 1989, N.E. J. Med. ~Q:265-271).
The cells were then incubated with either 1 ng/ml endotoxin (lipopolysaccharide, E. coli 055: B5, Sigma, St. Louis), or l0 to 1000 ng/ml ~-glucan, at 37°C for 24 hours in 5% COZ and then lysed by three freeze-thaw cycles (Endres et al., 1989, N.E. J. Med.
~Q:265-271) .
Synthesis of IL-is and TNFa was determined by specific radioimmunoassays as described elsewhere (Lisi stet al., 1987, lymph Res. _6:229-244; Lonnemann et ., 1988, Lvmnh. Res. 7:75-84; Van der Meer et ., 1988, J.
Leukocycte Biol. X3:216-223.
To determine if neutral soluble glucan could act as a priming agent for cytokine synthesis with endotoxin, a known cytokine stimulant, mononuclear cells were pre-incubated with 1, 10, and 1000 ng/ml of the neutral soluble glucan for 3 hours at 37°C in 5%
C02. The cells were washed to remove neutral soluble glucan and were then incubated with 1 ng/ml endotoxin as described above. IL-1~ and TNFa were determined as described above.
The results are summarized in Table 6. Neutral soluble glucan used as a stimulant at doses of 10-1000 ng/ml alone did not induce increased levels of IL-1~ or TNFa synthesis over the control buffer treated cells.
Endotoxin LPS, a known stimulant, resulted in signifi-cantly increased levels of both cytokines. In a second phase of this experiment neutral soluble glucan was tested for its ability to act as a priming agent for mononuclear cell cytokine synthesis. The cells from the same donors were pre-incubated with three doses of neutral soluble glucan (l0-1000 ng/ml) and were then exposed to endot:oxin as a co-stimulant. Neutral soluble glucan did volt result in any amplification of the IL-1~ and TDfFa le~~els compared to endotoxin alone.
Table 6 In Vitro IL-1~ and TNFa Synthesis by Human Peripheral Blood Mononuclear Cells Stimulant IL-1~ TNFa (ng/ml)' (ng/ml)' Cells only <0.10 0.14 Neutral 10 ng/ml 0.13 0.16 soluble glucan x.00 ng,~ml o .12 0.16 1000 ng,~ml <0.10 0.14 LPS 1 ng,~ml 2.62 2.22 LPS(1 ng/ml)+10 ng,~ml 2.62 2.25 Neutral soluble 1.00 ng,~ml 2.57 2.07 glucan 1000 ng/ml 2.85 2.27 'Values are the mean of two donors.

EXAMPLE 7: ~N VIVC~ PROTECTION AGAINST _ ~NFECTfON IN RATS , A sepsis model. was developed in rats to characterize the efficacy of ~-glucan in protecting an immunologically intact host against serious infections, such as those which. commonly occur following abdominal surgery. The rat model for intra-abdominal sepsis has been well described in the scientific literature (Onderdonk et al., 1974, Infect. Immun., X0:1256-1259).
Groups of rats received neutral soluble glucan (100 ~g/0.2 ml) or saline control (0.2 ml) intramuscularly 24 hours and 4 hours prior to infectious challenge. A defined polymicrobic infectious challenge (cecal inoculum) was placed into a gelatin capsule which was then surgically implanted into the peritoneal cavity of anesthetized rats through an anterior midline incision. The early peritonitis from this experimentally induced infection was associated with the presence of gram-negative organisms within the bl~~od and peritoneal cavity culminating in mortality. T:he cecal inoculum contained an array of facultative species, such ~ co ', as well as other obligate anaerobes (Streptococcus sp., Pacteroides sp., Clostridium perfrin ens, Clostridium ramosum, Peptostreptococcus ~naanus and productus, Proteus mira-bilis). The animals were observed four times per day for the first 48h and twice per day thereafter. The results are reported in Table 7.

Table ..7 Effect of Neutral So7Luble Glucan on Mortality in a Rat Model for Intra~-abdominal Sepsis Group Mortality(%1 P vs. Saline Saline 12/20 (60) Neutral soluble glucan 2/10 (10) < 0.01 These results demonstrate that neutral soluble glucan -- which does not .induce IL-1~ and TNFa protects rats from lethal bacterial challenge.
EXAMPLE 8: pEMnNSTRA'TION OF SAFETY FOR
SAN ADMINISTRATION
A randomized, double-blind, placebo-controlled clinical trial was conducted on healthy males to evaluate the safety of neutral soluble glucan (2.25 mg/kg) injected by intravenous infusion compared to a placebo control. No adverse effects were observed.
There was also :no observed elevation in IL-1, TNF, IL-6, IL-8 and GM-~CSF. Single intravenous administration of neutral soluble glucan resulted in an increase in mvnocytes and n~eutrophils and in the killing activity of these cells ;proving that neutral soluble glucan retains the desirable immunological activities in humans. See Tables 8, 9 and 10 below. However, as shown in Figures 5 and 6 no changes occurred in serum ' IL-1 and TNF and none of the patients experienced fever or inflammatory reactions. The results are consistent with the in vitro data reported in the earlier examples.

WO 94/04163 PCT/US93/07904 .,..

Table 8 Change In Absolute Neutrophil Counts (x 1000/1) After Neutral Soluble Glucan Administration Dose Level B Hour 8 Hour 12 Hour 24 Saline Mean 4.06 4.34 4.31 3.43 SD~ 2.12 1.53 1.16 1.46 IO 2.5 mg/kg Mean 4.11 11.29' 8.18 5.32 Neutral SDI 1.15 4.39 3.80 1.75 Soluble N' 6 6 6 6 Glucan I5 B = Baseline a~easurE:ment ' p < 0.01 with respect to baseline Table 9 Change: in Monocyte Counts (X 1000/~C1) After Soluble Administration Neutral Glucan Dose Level B Hour 8 Hour 12 Hour Saline Mean 0.33 0.44 0.59 0.33 SD 0.09 0.10 0.22 0.12 2.5 mg/kg Mean 0.24 0.63' 0.67' 0.31 Neutral SD 0.10 0.24 0.32 0.15 Soluble N 6 6 6 6 Glucan B = Baseline measurement p < 0.01 with respect baseline to Table 10 ~x Vivo Microbicidal Activity of Nonaal Volunteers Receiving Neutral Soluble Glucan Mean Change in % Killing' Dose Level Hour Hour 6 Hour 24 Day 2 Day 3 Day Saline 0 0 0 0 0 0 2.5 mg/kg Mean 42.86 32.33 20.90 48.96 39.22 31.17 Neutral N 6 6 6 6 6 6 Soluble p-Value 0.062 0.036 0.300 0.045 0.085 0.026 Glucan 1 Normalized with respect to the saline control EXAMPLE 9: ~MONSTRATION OF EFFICACY IN VIVO AS
OMAN ANTI- INFECTIVE ' In this clinical study, the safety, tolerance, and potential e:Eficac.y of the neutral soluble ~-glucan was evaluated in patients undergoing major thoracoabdominal surgery with high risk of post-operative infection.
Thirty-four males and females who underwent surgery received 0. l5 mg/k~g of the neutral soluble ~-glucan preparation or saline placebo, given as an intravenous infusion of 50 to 200 ml over one hour. Patients received multiple sequential doses of the neutral soluble ~-g:lucan or placebo at 12 to 24 hours prior to surgery, 1 to 4 hours prior to surgery, 48 hours post-surgery, an~3 96 hours post-surgery.
Hospitalization, infections, and usage of anti-infective medications were examined as potential clinical efficacy parameters. Compared to patients given saline placebo infusions, patients who received the neutral soluble ~=glucan spent an average of five fewer days in the hospital (12.3 ~ 6.1 days versus 17.3 + 15.5 days) and three fewer days in the Intensive Care Unit (0.1 ~ 0.4 versus 3.3 + 6.3 days; p<0.03, one-way analysis of variance).
The number o~f anti-infective medication prescrip-tions written per study day following surgery was consistently higher for control patients than for ~-glucan recipient patients. Control patients were prescribed an average of three times the number of anti-infective medications as ~-glucan recipients over the time period from surgery to discharge (p<0.005).
During the Treatment and Post-Treatment Follow-up Phases, a total of 22 culture-confirmed infections in 5 control patients and 8 infections in 5 ~-glucan recipient patienta were identified (p<0.002).
Neutrophils (PMNs) and monocytes/macrophages (MOs) were purified from blood samples obtained at Baseline, fB

'~°~ 94/04163 2 ~ 4 2 ~ ~ ~ PCT/US93/07904 Day 1, and Day !i and examined for basal and phorbol myrisate acetatc= stimulated microbicidal activity against Etavhylc~coccus aureus, Escherichia coli and Candida albicanaz. The neutral soluble ~-glucan treatment gener~illy increased the basal and phorbol-induced microbic:idal activity of MOs and PMNs.
EXAMPLE 10: W_OUtJD HEALING EFFECTS OF NEUTRAL
SOLZJBLE GLUCANS
Wound healing studies were performed in a hairless mouse model hav:lng full thickness wounds with and 5 without Sta~h~lc~coccus aureus infection. Hairless SKH-1 inbred mice (ci-8 weeks of age) were anesthetized with ether and a mid:line 3 cm full thickness longitudinal incision was made with a number 10 scalpel blade, producing a full thickness wound that did not penetrate the underlying ~Eascia. Incisions were closed using steel clips placed at 1 cm intervals.
Formulations of neutral soluble glucan in phos-phate buffered a~aline were applied 30 minutes following wounding and re~spplied at 24 hour intervals during the seven day post-operative period. Two micrograms of neutral soluble glucan/mouse per day was topically applied. Wound: were examined daily and rank-ordered for effectiveness of formulation for enhancement of visual based wound healing. Wounds were scored for closure on a sc~ile of 0-5, with 5 indicating the most healing. In on~~ graup of mice infected, the wound was treated with a ~~ulture of 10' Staphylococcus aureus 30 minutes after w~~undxng and 2 hrs prior to treatment with the neutra:L soluble glucan formulation.
Histologic~~l evaluation of the wound site of each test group was ~nade» The dermis of the control group (untreated wound) was heavily infiltrated with both lymphocytes and monocytes/macrophages. However, re-WO 94/04163 PCT/US93/079P~
~1~~811 epithelialization that occurred at the epidermal layer was incomplete. The tissue section showed that the dermal tissue was weak, in that the tissue integrity was not maintained when it was sectioned.
The histology of the wounded tissue isolated from mice treated for three days with phosphate buffered saline containing the neutral soluble glucan showed that there was a heavy infiltration of macrophages and lymphocytes. Tissue integrity was good.
When topically applied to a wound, a composition of neutral soluble glucan stimulated white blood cell entry and activity at the wound site and accelerated wound healing within the dermal layer of the wound.
Furthermore, the composition effectively eliminated infection produced by bacterial infection (S,_. aureus) and prevented the progression to sepsis. Untreated wounds progressed to sepsis.
EXAMPLE 11: ,S'T'Tt~ttt~,TION OF PLATELET PROLIFERATION BY
~1EUTRAL SOLUBLE GLUCAN
The platelet proliferation stimulatory effect of the neutral soluble glucan was tested in an animal model system following either irradiation or administration of the chemotherapeutic agent cisplatin.
These experiments demonstrated the unexpected platelet stimulatory effect.
More specifically, saline or neutral soluble glucan prepared as described in Example 1 was administered to groups of 10 mice as a single IV bolus 20 hours prior to radiation exposure. Mice were bilaterally exposed to a total-body irradiation of 7.5-Gy. Fourteen days after irradiation the mice were sacrificed and whole blood samples were analyzed for la~'O 94/04163 PC1'/US93/07904 peripheral blood counts. As shown in Figure 7, the platelet cell count from neutral soluble glucan-treated mice was increased nearly 3-fold relative to saline-treated control. levels.
In addition to tests on irradiated mice, cisplatin-treated mice were also tested for the effect of the neutral soluble glucan on platelet hematopoiesis. Balb/c mice were injected intravenously with cisplatin at a dose of 9.3 mg/kg through the tail vein one hour lr~efore injecting either saline or the neutral soluble glucan, prepared as described in Example 1, intramuscularly in a single dose of 0 (saline) or 2 a~g/kg on Day 0. Platelet counts were determined before treatment (Day 0) and at 2, 4, 6, 8, and 10 days post-treatment. The results of this experiment are shown in Figure 8. Each data point represents the mean and standard error of platelet counts from five mice. The statistically significant differences (p<0.05) between the saline and neutral soluble glucan (2 mg/kg) are noted.
Biological Depcs_it Saccharomvces cerevisiae strain R4 Ad was deposited on August 20, 1992 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, under the terms of the Budapest Treaty. The strain has been assigned ATCC accession number 74181. Upon issuance of a patent, this deposit will be irrevocable.

~cruivalents Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific materials and components described herein. Such equivalents are intended to be encompassed in the scope of the following claims:

Claims (41)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro.
2. The underivatized, aqueous soluble .beta.(1-3) glucan of Claim 1 wherein the glucan is derived from yeast or yeast whole glucan particles.
3. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties which when incubated for greater than 3 hours at a concentration of about 1 µg/ml with a human peripheral blood mononuclear cell culture of about 5 X
6 cells/ml, results in a less than 2-fold increase in interleukin-1.beta. and tumor necrosis factor-.alpha. synthesis over levels obtained following an otherwise identical incubation with a buffered solution lacking a .beta.(1-3) glucan component.
4. The underivatized, aqueous soluble .beta.(1-3) glucan of Claim 3 wherein the glucan is derived from yeast or yeast whole glucan particles.
5. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties which when incubated for greater than 3 hours at a concentration of about 1 µg/ml with an endotoxin-stimulated human peripheral blood mononuclear cell culture of about 5 X 10 6 cells/ml, results in a less than 2-fold increase in interleukin-1.beta. and tumor necrosis factor-.alpha. synthesis over levels obtained with endotoxin stimulation alone.
6. The underivatized, aqueous soluble .beta.(1-3) glucan of Claim 5 wherein the glucan is derived from yeast or yeast whole glucan particles.
7. An underivatized, aqueous soluble .beta.(1-3) glucan having immunostimulating properties that is in a triple helix conformation which when mixed at a concentration of 1 mg/ml with aniline blue forms a fluorescent complex in 25 mM NaOH and which loses about 50% of that fluorescence in 150 mM NaOH, said glucan does not stimulate or prime production of interleukin-1, tumor necrosis factor or both, in vitro.
8. The underivatized, aqueous soluble .beta.(1-3) glucan of Claim 7 wherein the glucan is derived from yeast or yeast whole glucan particles.
9. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties, wherein the soluble glucan when intrave-nously injected into a human will not significantly increase the levels of interleukin-1 or tumor necrosis factor or both in the serum of said human.
10. The underivatized, aqueous soluble .beta.(1-3) glucan of Claim 9 wherein the glucan is derived from yeast or yeast whole glucan particles.
11. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation and having an average molecular weight of from about 30, 000 to about 300, 000 daltons, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro or in vivo.
12. An underivatized, aqueous soluble yeast .beta.(1-3) glucan in a triple helix conformation and having an average molecular weight of from about 30, 000 to about 500, 000 daltons, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro or in vivo.
13. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties and when analyzed by gel permeation undergoes a conformational transition from a multiple helix at pH 7 to a single helix conformation at pH 13, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro or in vivo.
14. A composition comprising an underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties, in a physio-logically acceptable vehicle, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro.
15. The composition of Claim 14 wherein the physiologically acceptable vehicle is water, sterile saline, phosphate buffered saline, isotonic saline or dextrose.
16. The composition according to Claim 14 or 15 wherein the concentration of glucan in the physiologically acceptable vehicle is from about 0.5 to 100 mg/ml.

-47a-
17. The composition according to any one of Claims 14 to 16 wherein the composition is in the form of a liquid, tablet, gel, ointment, lotion, capsule, powder, solution, emulsion or cream.
18. The composition according to any one of Claims 14 to 17 wherein the underivatized, aqueous soluble .beta.(1-3) glucan has an average molecular weight of from about 30,000 to about 300,000 daltons.
19. A composition comprising an underivatized, aqueous soluble yeast .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties, in a physiologically acceptable vehicle, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro.
20. The composition of Claim 19 wherein the physiologically acceptable vehicle is water, sterile saline, phosphate buffered saline, isotonic saline or dextrose.
21. The composition according to Claim 19 or 20 wherein the concentration of glucan in the physiologically acceptable vehicle is from about 0.5 to 100 mg/ml.
22. The composition according to any one of Claims 19 to 21 wherein the composition is in the form of a liquid, tablet, gel, ointment, lotion, capsule, powder, solution, emulsion or cream.
23. The composition according to any one of Claims 19 to 22 wherein the underivatized, aqueous soluble .beta.(1-3) glucan has an average molecular weight of from about 30,000 to about 500,000 daltons.
24. A process for producing an underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties, comprising the steps of:
a) treating a suspension of insoluble glucan with an acid to dissolve the acid-soluble portion of the glucan;
b) treating the acid-soluble glucan with alkali to denature the native conformation of the soluble glucan;
c) neutralizing the solution containing the denatured soluble glucan to re-anneal the soluble glucan; and d) purifying the re-annealed soluble glucan to obtain an underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro.
25. The process of Claim 24 wherein step (a) is performed at a pH of from about 1 to about 5 and a temperature of from about 20°C to about 100°C.
26. The process according to Claim 24 or 25 wherein the acid is acetic acid at a concentration of from about 0.1 to about 5M or formic acid at a concentration of from about 50% to about 98% (w/v).
27. The process according to any one of Claims 24 to 26 wherein step (b) is performed at a pH of from about 7 to about 14 and a temperature of from about 4°C to about 121°C.
28. The process according to any one of Claims 24 to 27 further comprising the step of purifying the denatured glucan prior to step (c) to remove aqueous insoluble glucans and aggregated aqueous soluble glucans therefrom.
29. The process according to any one of Claims 24 to 28 wherein the purification step is performed using 1000 to 100,000 dalton ultrafilters.
30. The process according to any one of Claims 24 to 29 wherein step (c) is performed at a pH of about 6 to 8 and at a temperature of from about 50°C to 70°C.
31. The process according to any one of Claims 24 to 30 wherein step (d) is performed using a 30,000 to 100,000 nominal molecular weight (NWM) ultrafilter and a 150,000 to 500,000 NWM ultrafilter.
32. The process according to any one of Claims 24 to 31 wherein the glucan is derived from yeast or yeast whole glucan particles.
33. An underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro, produced by the process according to any one of Claims 24 to 32.
34. An underivatized, aqueous soluble yeast .beta.(1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro, produced by the process according to any one of Claims 24 to 32.
35. A process for producing an underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation, comprising the steps of:
a) treating a suspension of insoluble glucan with an acid at a pH of from about 1 to about 5 and a temperature of from about 20°C to about 120°C to dissolve the acid-soluble portion of the glucan;
b) treating the acid-soluble glucan with alkali at a pH of from about 7 to about 14 and a temperature of from about 4°C to about 121°C to denature the native conformation of the soluble glucan;
c) neutralizing the solution containing the denatured soluble glucan to re-anneal the soluble glucan; and d) purifying the re-annealed soluble glucan to obtain an underivatized, aqueous soluble .beta.(1-3) glucan in a triple helix conformation.
36. The process of Claim 35 wherein the glucan is derived from yeast or yeast whole glucan particles.
37. An underivatized, aqueous soluble .beta.(1-3)-glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro, produced by the process of Claim 35 or 36.
38. An underivatized, aqueous soluble .beta.(1-3) glucan according to any one of Claims 1 to 13, 33, 34 or 37 for use in (i) preventing infection in a mammal that is at risk for infection;
(ii) stimulating repair and healing of a wound site on a mammal;
(iii) stimulating platelet proliferation;
(iv) enhancing microbicidal activity of phagocytic cells;
(v) stimulating hematopoiesis; or (vi) stimulating the proliferation of monocytes and neutrophils;
(vii) treating refractory infections; and (viii) enhancing the immune response of a mammal without stimulating production of biochemical mediators that cause detrimental side effects in said mammals.
39. Use of an underivatized, aqueous soluble .beta.(1-3) glucan according to any one of Claims 1 to 13,33,34 or 37 for the manufacture of a medicament for use in (i) preventing infection in a mammal that is at risk for infection;
(ii) stimulating repair and healing of a wound site on a mammal;
(iii) stimulating platelet proliferation;
(iv) enhancing microbicidal activity of phagocytic cells;
(v) stimulating hematopoiesis, or (vi) stimulating the proliferation of monocytes and neutrophils;
(vii) treating refractory infections; and (viii) enhancing the immune response of a mammal without stimulating production of biochemical mediators that cause detrimental side effects in said mammals.
40. A composition according to any one of Claims 14 to 23 for use in (i) preventing infection in a mammal that is at risk for infection;
(ii) stimulating repair and healing of a wound site on a mammal comprising;
(iii) stimulating platelet proliferation;
(iv) enhancing microbicidal activity of phagocytic cells by administering to a mammal an effective amount of the .beta.(1-3) glucan or glucan composition;
(v) stimulating hematopoiesis, or (vi) stimulating the proliferation of monocytes and neutrophils;
(vii) treating refractory infections; and (viii) enhancing the immune response of a mammal without stimulating production of biochemical mediators that cause detrimental side effects in said mammals.
41. A composition according to any one of Claims 14 to 23 for the manufacture of a medicament for use in (i) preventing infection in a mammal that is at risk for infection;
(ii) stimulating repair and healing of a wound site on a mammal;
(iii) stimulating platelet proliferation;
(iv) enhancing microbicidal activity of phagocytic cells;
(v) stimulating hematopoiesis; or (vi) stimulating the proliferation of monocytes and neutrophils;
(vii) treating refractory infections; and (viii) enhancing the immune response of a mammal without stimulating production of biochemical mediators that cause detrimental side effects in said mammals.
CA002142811A 1992-08-21 1993-08-20 Novel glucan preparation Expired - Lifetime CA2142811C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/934,015 1992-08-21
US07/934,015 US5622939A (en) 1992-08-21 1992-08-21 Glucan preparation
PCT/US1993/007904 WO1994004163A1 (en) 1992-08-21 1993-08-20 Novel glucan preparation

Publications (2)

Publication Number Publication Date
CA2142811A1 CA2142811A1 (en) 1994-03-03
CA2142811C true CA2142811C (en) 2006-10-31

Family

ID=26786977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142811A Expired - Lifetime CA2142811C (en) 1992-08-21 1993-08-20 Novel glucan preparation

Country Status (2)

Country Link
CA (1) CA2142811C (en)
NO (1) NO950634L (en)

Also Published As

Publication number Publication date
NO950634D0 (en) 1995-02-20
NO950634L (en) 1995-04-20
CA2142811A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
US5817643A (en) Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same
US5532223A (en) Use of aqueous soluble glucan preparations to stimulate platelet production
US5504079A (en) Method for immune system activation by administration of a β(1-3) glucan which is produced by Saccharomyces cerevisiae strain R4
AU650626B2 (en) Method for producing soluble glucans
US5811542A (en) Method for producing soluble glucans
US6369216B1 (en) Very high molecular weight β-glucans
US7566704B2 (en) Very high molecular weight β-glucans
Di Luzio Update on the immunomodulating activities of glucans
EP0506325B1 (en) Guluronic acid polymers and use of same for inhibition of cytokine production
EP1448215B1 (en) Use of laminarin in the treatment of cancer
CA2142811C (en) Novel glucan preparation
AU679690C (en) Novel glucan preparation
EP0611304B1 (en) Use of acetylated mannan (acemannan) for the regulation of blood cholesterol levels and for removing plaques in blood vessels

Legal Events

Date Code Title Description
EEER Examination request